Does Rallies show 13F holders for OCUL?

Yes. Rallies tracks hedge fund and 13F ownership data for OCUL, including fund names, share counts, latest tracked quarter, and position changes when available.

Is OCUL research on Rallies investment advice?

No. Rallies provides research, data, and educational context for OCUL. It does not provide personalized investment advice.

OCUL (Ocular Therapeutix, Inc.) Stock Analysis - Hedge Fund Holdings

Ocular Therapeutix, Inc. (OCUL) is a publicly traded Healthcare sector company. As of May 21, 2026, OCUL trades at $8.08 with a market cap of $1.83B and a P/E ratio of -5.63. OCUL moved +0.38% today. Year to date, OCUL is -30.48%; over the trailing twelve months it is +5.66%. Its 52-week range spans $5.79 to $16.44. Analyst consensus is strong buy with an average price target of $24.50. Rallies surfaces OCUL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns OCUL stock?

Hedge funds tracked by Rallies that own OCUL include Orbimed Advisors, Panagora Asset, Mangrove Partners, and Farallon Capital. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Ocular Therapeutix, Inc..

OCUL Key Metrics

Key financial metrics for OCUL
Metric	Value
Price	$8.08
Market Cap	$1.83B
P/E Ratio	-5.63
EPS	$-1.44
Dividend Yield	0.00%
52-Week High	$16.44
52-Week Low	$5.79
Volume	4.62K
Avg Volume	0
Revenue (TTM)	$52.04M
Net Income	$-290.50M
Gross Margin	87.24%

Top Hedge Funds Holding OCUL

Orbimed Advisors holds 157.30K shares of OCUL, changed +0.00% as of Dec 31, 2025.
Panagora Asset holds 94.53K shares of OCUL, changed -68.12% as of Mar 31, 2026.
Mangrove Partners holds 21.42K shares of OCUL, changed +0.00% as of Sep 30, 2024.
Farallon Capital holds 18.00K shares of OCUL, changed +0.00% as of Mar 31, 2026.

Latest OCUL News

Ocular Therapeutix Q1 Loss of $88.6M, AXPAXLI Phase 3 Shows 65.9% Vision Maintenance — May 5, 2026
Ocular Therapeutix Enrolls First Patient in Three-Year SOL-X Extension Trial for AXPAXLI — Apr 29, 2026
Ocular Therapeutix to Present Phase 3 SOL-1 Results May 5, Host Two Investor Fireside Chats — Apr 27, 2026
Ocular Therapeutix’s AXPAXLI Outlasts Aflibercept by 23 and 22 Weeks in SOL-1 Trial — Apr 13, 2026
Ocular Therapeutix to Present SOL-1 Phase 3 AXPAXLI Data on April 11 and 15 — Apr 1, 2026

Recent OCUL Insider Trades

Dugel Pravin sold 20.06K (~$166.06K) on Feb 23, 2026.
Kaiser Peter sold 2.81K (~$23.27K) on Feb 23, 2026.
Heier Jeffrey S. sold 3.06K (~$25.31K) on Feb 23, 2026.

OCUL Analyst Consensus

9 analysts cover OCUL: 0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $24.50.

Common questions about OCUL

Who owns OCUL stock?: Hedge funds tracked by Rallies that own OCUL include Orbimed Advisors, Panagora Asset, Mangrove Partners, and Farallon Capital. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Ocular Therapeutix, Inc..
Does Rallies show 13F holders for OCUL?: Yes. Rallies tracks hedge fund and 13F ownership data for OCUL, including fund names, share counts, latest tracked quarter, and position changes when available.
Is OCUL research on Rallies investment advice?: No. Rallies provides research, data, and educational context for OCUL. It does not provide personalized investment advice.